Results 41 to 50 of about 22,655 (236)

Involvement of the CB2 cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212–2 in renal cell carcinoma

BMC Cancer, 2018
Background The anti-tumor properties of cannabinoids have been investigated in many in vitro and in vivo studies. Many of these anti-tumor effects are mediated via cannabinoid receptor types 1 and 2 (CB1 and CB2), comprising the endocannabinoid system ...
Mohammed I. Khan, Anna A. Sobocińska, Klaudia K. Brodaczewska, Katarzyna Zielniok, Malgorzata Gajewska, Claudine Kieda, Anna M. Czarnecka, Cezary Szczylik   +7 more
doaj   +1 more source

Feeding induced by cannabinoids is mediated independently of the melanocortin system. [PDF]

PLoS ONE, 2008
Cannabinoids, the active components of marijuana, stimulate appetite, and cannabinoid receptor-1 (CB1-R) antagonists suppress appetite and promote weight loss.
Puspha Sinnayah, Erin E Jobst, Joseph A Rathner, Angela D Caldera-Siu, Luciana Tonelli-Lemos, Aaron J Eusterbrock, Pablo J Enriori, Emmanuel N Pothos, Kevin L Grove, Michael A Cowley   +9 more
doaj   +1 more source

Significance of Cannabinoid CB1 Receptors in Improgan Antinociception [PDF]

The Journal of Pain, 2007
Improgan is a congener of the H(2) antagonist cimetidine, which produces potent antinociception. Because a) the mechanism of action of improgan remains unknown and b) this drug may indirectly activate cannabinoid CB(1) receptors, the effects of the CB(1) antagonist/inverse agonist rimonabant (SR141716A) and 3 congeners with varying CB(1) potencies were
Neal C, Gehani, Julia W, Nalwalk, Raj K, Razdan, Billy R, Martin, Xufung, Sun, Mark, Wentland, Mary E, Abood, Lindsay B, Hough   +7 more
openaire   +2 more sources

Heteromerización de receptores de adenosina A2A, dopamina D2 y cannabinoides CB1. Implicaciones farmacológicas y funcionales. [PDF]

, 2007
[spa] La visión de los receptores acoplados a proteína G ha evolucionado en los últimos años. Clásicamente se consideraban unidades individuales capaces de producir una señal intracelular; actualmente, está aceptado que estas proteínas de membrana pueden
Carriba Domínguez, Paulina
core  

Cannabidiol in Anorexia Nervosa: A Double‐Blind Randomized Placebo Controlled Pilot Study to Test Safety, Pharmacokinetics, and Symptom Change

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Anorexia nervosa (AN) is a severe psychiatric disorder marked by an intense fear of gaining weight and persistent body dissatisfaction, both during periods of underweight and after weight restoration. The endocannabinoid system may offer therapeutic benefits, particularly in reducing anxiety.
Neha Sahota, David J. Grelotti, Tyler Nguyen, Walter H. Kaye, Skylar Swindle, Raymond Suhandynata, Spencer Seely, Megan E. Shott, Guido K. W. Frank   +8 more
wiley   +1 more source

Prediction of essential binding domains for the endocannabinoid N-arachidonoylethanolamine (AEA) in the brain cannabinoid CB1 receptor.

PLoS ONE, 2021
Δ9-tetrahydrocannabinol (Δ9-THC), the main active ingredient of Cannabis sativa (marijuana), interacts with the human brain cannabinoid (CB1) receptor and mimics pharmacological effects of endocannabinoids (eCBs) like N-arachidonylethanolamide (AEA). Due
Joong-Youn Shim
doaj   +1 more source

R-flurbiprofen reduces neuropathic pain in rodents by restoring endogenous cannabinoids [PDF]

, 2010
Background: R-flurbiprofen, one of the enantiomers of flurbiprofen racemate, is inactive with respect to cyclooxygenase inhibition, but shows analgesic properties without relevant toxicity. Its mode of action is still unclear.
Geisslinger, Gerd, Gerd Geisslinger, Ziebell Simone, Julia Metzner, Ziebell, Simone, Koch, Marco, Myrczek, Thekla, Marian, Claudiu, Dehghani, Faramarz, Rohini Kuner, Schmidt Helmut, Bechmann Ingo, Marian Claudiu, Nina Wijnvoord, Dehghani Faramarz, Philipp Bishay, Bishay, Philipp, Kuner, Rohini, Helmut Schmidt, Faramarz Dehghani, Koch Marco, Bechmann, Ingo, Metzner, Julia, Geisslinger Gerd, Irmgard Tegeder, Tegeder Irmgard, Simone Ziebell, Wijnvoord, Nina, Tegeder, Irmgard, Claudiu Marian, Kuner Rohini, Costigan, Michael, Wijnvoord Nina, Annett Häussler, Ingo Bechmann, Michael Costigan, Schmidt, Helmut, Häussler, Annett, Bechmann, Ingo Jürgen, Myrczek Thekla, Bishay Philipp, Häussler Annett, Marco Koch, Costigan Michael, Thekla Myrczek, Metzner Julia   +45 more
core   +1 more source

A consensus roadmap for post‐traumatic epilepsy: Clinical biomarkers, research priorities, policy barriers, and pathways to interventional trials

Epilepsia, EarlyView.
Abstract Understanding the mechanisms underlying post‐traumatic epilepsy (PTE) following traumatic brain injury (TBI), and developing strategies to prevent or modify its progression, has been the focus of large collaborative efforts within the epilepsy and TBI research communities for over a decade.
Elisa R. Zanier, Ilaria Lisi, Elaine K. O'Loughlin, Federico Moro, Edilberto Amorim, David L. Brody, Daniel J. Correa, Dominique Duncan, Pavel Klein, Firas H. Kobeissy, Wolfgang Löscher, Edward J. Needham, Asla Pitkänen, Mary Jo Pugh, Jack Somers, Annamaria Vezzani, Amy K. Wagner, Laura S. Lubbers, International Conference on PTE Attendees, Denes Agoston, Edilberto Amorim, Sneha Anand, Hibah Awwad, Ginevra Bayon, Naima Belhachemi, Akash Bera, Costanza Bertani, Guido Bertolini, David L. Brody, Serena Brusatori, Francesca Buffelli, Aurora Chiapperini, Mara Chioccola, Severn Churn, Daniel J. Correa, Ramon Diaz‐Arrastia, Chris Dulla, Dominique Duncan, Chiara Ferlito, Aristea Galanopoulou, Angela Galic, Heidi Matos Galicia, Bin Gu, William Haskins, Victoria Johnson, Nigel Jones, Lowie Joseph, Pavel Klein, Firas Kobaissy, Ilaria Lisi, David Loane, Luther Loose, Laura S. Lubbers, Wolfgang Löscher, Edoardo Mazzone, Melissa Miller, Federico Moro, Edward J. Needham, Irma Wati Ngadimon, Terence O’Brien, Elaine K. O’Loughlin, Asla Pitkanen, Mary Jo Pugh, Teresa Giovanna Ravizza, Giuseppe Remuzzi, Massimo Rizzi, Rossella Di Sapia, Tawfeeq Shekh‐Ahmad, Doug Smith, Jack Somers, Kevin Staley, Francesca Tribuzio, Alexandra Ulyanova, Gloria Vegliante, Annamaria Vezzani, Joost Wagenaar, Amy K. Wagner, Kevin W. Wang, Justin Weppner, Peter J. West, Karen Wilcox, John Wolf, Elisa R. Zanier   +82 more
wiley   +1 more source

Subsynaptic Distribution, Lipid Raft Targeting and G Protein-Dependent Signalling of the Type 1 Cannabinoid Receptor in Synaptosomes from the Mouse Hippocampus and Frontal Cortex

Molecules, 2021
Numerous studies have investigated the roles of the type 1 cannabinoid receptor (CB1) in glutamatergic and GABAergic neurons. Here, we used the cell-type-specific CB1 rescue model in mice to gain insight into the organizational principles of plasma ...
Miquel Saumell-Esnaola, Sergio Barrondo, Gontzal García del Caño, María Aranzazu Goicolea, Joan Sallés, Beat Lutz, Krisztina Monory   +6 more
doaj   +1 more source

Cannabidiol reduces atypical absence seizures and epileptic spasms in a Gabrb3+/D120N mouse model of Lennox–Gastaut syndrome

Epilepsia Open, EarlyView.
Abstract Objective Lennox–Gastaut syndrome (LGS) is a drug‐resistant developmental and epileptic encephalopathy (DEE). Preclinical drug development for LGS is constrained by a lack of syndrome‐relevant animal models. We aimed to evaluate a Gabrb3+/D120N knock‐in (KI) mouse model of LGS by quantifying atypical absence seizures and epileptic spasms and ...
Thomas Harman, Laura A. Sharman, Ka Lai Yip, Miguel Bedoya‐Pérez, Vaishali Janve, Jonathon C. Arnold   +5 more
wiley   +1 more source